Hikal Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
HIKAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 11.5 pts less than Nifty Microcap 250 and 11.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Hikal Limited reported a net loss of Rs 487 million for FY2025-26, a sharp decline from profit of Rs 909 million in the previous year. Total revenue from operations fell to Rs 17,126 million from Rs 18,598 million, representing a 7.9% decline, impacted by USFDA warning letter for Jigani facility affecting Pharma segment sales. Exceptional items of Rs 851 million include impairment charge of Rs 471 million for assets at a repurposed plant and Rs 380 million from new labour code implementation (gratuity and compensation policy changes). Operating cash flow remained healthy at Rs 3,021 million. The Board recommended reduced dividend of 30% (Rs 0.60 per share) vs 70% in prior year. Auditors gave unmodified opinion with emphasis of matter on pending Supreme Court case regarding environmental compliance and Rs 174.5 million compensation claim.
The company swung to a loss due to exceptional items and revenue decline. Shareholders face reduced dividend and ongoing regulatory risks from USFDA warning letter and environmental litigation. The stock may remain under pressure until regulatory issues are resolved.